EUVIMEDEUVIMED entdecken
Crossref

Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine

Diego Ripamonti iD, Alberto Borghetti, Maurizio Zazzi

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Diego Ripamonti und 2 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Pyridones, Anti-HIV Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current high-genetic-barrier regimens (either boosted PI- or second-generation integrase inhibitor-based options), allow long-term control of HIV replication in people living with HIV (PLWH). However, maintaining medication adherence may be challenging over time for a number of reasons.1 The recent availability of long-acting (LA) injectable cabotegravir and rilpivirine as a switch dual regimen given intramuscularly every 8 weeks is a breakthrough in ART simplification. Indeed, a total of five Phase 2/3 randomized trials2–7 consistently demonstrated the non-inferiority of LA cabotegravir and rilpivirine therapy compared with the standard oral treatment over 124–256 weeks of follow-up, with a 1%–2% risk of virological failure (VF, defined as two consecutive plasma HIV-1 RNA levels of >200 copies/mL).8 Viral blips, defined as isolated HIV-1 RNA values between 50 and 200 copies/mL, were detected at comparable rates in the LA cabotegravir and rilpivirine and comparator arms, both in the FLAIR study (i.e. dolutegravir/abacavir/lamivudine versus LA cabotegravir and rilpivirine given once monthly, rate of blips: 17% and 16%, respectively, over 96 weeks) and in the ATLAS-2M study (i.e. LA cabotegravir and rilpivirine given once monthly versus bimonthly, rate of blips: 9% and 8%, respectively, over 152 weeks).9 Importantly, viral blips were not associated with a higher risk of failure, therefore they should be considered as neither unexpected nor alarming by both clinicians and patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirineHIV InfectionsPyridonesAnti-HIV AgentsHumansViral LoadMaleDrug MonitoringMiddle AgedHIV-1FemaleAdultInjectionsDiketopiperazines

Substanzen

RilpivirinecabotegravirPyridonesAnti-HIV AgentsDiketopiperazines

Autor:innen und Institutionen

  • Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Infectious Diseases Clinic, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Department of Medical Biotechnology, University of Siena, Siena, Italy.

ORCID-Profile: Diego Ripamonti

Zitieren

APA

Ripamonti, D., Borghetti, A., & Zazzi, M. (2024). Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae257

Vancouver

Ripamonti D, Borghetti A, Zazzi M. Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae257

BibTeX
@article{Ripamonti2024,
  author = {Ripamonti, Diego and Borghetti, Alberto and Zazzi, Maurizio},
  title = {Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae257}
}
Kostenlos starten →